Patent · US Active

Compositions and methods for inhibiting gene expression of Hif2alpha

US11840688B2 · kind B2 · utility

0Cited by

7References

20Claims

0Family size

Assignee

Arrowhead Pharmaceuticals, Inc. · US

Inventors

So Wong · Oregon, US
David L. Lewis · Madison, US
David B. Rozema · Madison, US
Darren H. Wakefield · Fitchburg, US
Steven B. Kanner · Berkeley, US
Weijun Cheng · Middleton, US
Lauren J. Almeida · Madison, US
Andrei V. Blokhin · Fitchburg, US
Jeffrey C. Carlson · Madison, US
Anthony Nicholas · Oregon, US
Aaron Almeida · Madison, US
Jonathan D. Benson · Stoughton, US
Justin Woods · Fitchburg, US

Key dates

Filing date	Feb 19, 2021
Grant date	Dec 12, 2023
Priority date	—
Expiry date	Jul 6, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2α (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2α RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2α RNAi triggers to tumor cells in vivo provides for inhibition of Hif2α gene expression and treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.